Precision BioSciences develops gene editing therapies based on its proprietary ARCUS platform, which uses compact, highly specific nucleases to edit DNA in living cells for therapeutic purposes. Its pipeline targets in vivo gene correction for genetic diseases, including programs for Duchenne muscular dystrophy and other rare conditions with high unmet medical need. The technology supports precise insertions, excisions, and other complex edits delivered via AAV vectors.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -23.5 | — |
| Q3 2025 | 0 | — | -21.8 | — |
| Q4 2025 | 34.2 | — | 20.1 | — |
| Q1 2026 | 10.8 | — | -18.4 | — |
| Q2 2026 | 0 | -100% | -32.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Paloma Acquisition Corp I (PALO), GDEV Inc. (GDEV), NovaBridge Biosciences (NBP), Pro-Dex, Inc. (PDEX), QuickLogic Corporation (QUIK), Translational Development Acquisition Corp. (TDAC)